{"organizations": [], "uuid": "c6099e82ef3f22ab6cb88704f26359eb0a6cbbd6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-psivida-granted-waiver-by-the-fda/brief-psivida-granted-waiver-by-the-fda-for-new-drug-application-filing-fee-idUSASB0BZPW", "country": "US", "domain_rank": 408, "title": "BRIEF-Psivida Granted Waiver By The FDA For New Drug Application Filing Fee", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T14:23:00.000+02:00", "replies_count": 0, "uuid": "c6099e82ef3f22ab6cb88704f26359eb0a6cbbd6"}, "author": "", "url": "https://www.reuters.com/article/brief-psivida-granted-waiver-by-the-fda/brief-psivida-granted-waiver-by-the-fda-for-new-drug-application-filing-fee-idUSASB0BZPW", "ord_in_thread": 0, "title": "BRIEF-Psivida Granted Waiver By The FDA For New Drug Application Filing Fee", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "psivida corp", "sentiment": "none"}, {"name": "psivida corp", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 12:24 PM / in 9 minutes BRIEF-Psivida Granted Waiver By The FDA For New Drug Application Filing Fee Reuters Staff \nJan 4 (Reuters) - Psivida Corp: \n* PSIVIDA GRANTED WAIVER BY THE FDA FOR NEW DRUG APPLICATION FILING FEE \n* PSIVIDA CORP - ON TRACK TO FILE DURASERT NDA IN EARLY JANUARY \n* PSIVIDA - FDA GRANTED BUSINESS WAIVER OF PDUFA FEE OF ABOUT $2.4 MILLION FOR NDA FOR COâ€˜S DURASERT 3 YEAR MICROINSERT FOR POSTERIOR SEGMENT UVEITIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T14:23:00.000+02:00", "crawled": "2018-01-04T14:36:09.019+02:00", "highlightTitle": ""}